

Methanex Corporation

Consolidated Statements of Income (Loss) *(unaudited)*

(thousands of U.S. dollars, except number of common shares and per share amounts)

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Revenue	\$ 810,349	\$ 434,853
Cost of sales and operating expenses	(559,314)	(403,751)
Depreciation and amortization	(55,972)	(52,979)
Operating income (loss)	195,063	(21,877)
Earnings (loss) of associate (note 4)	16,989	(227)
Finance costs	(23,317)	(21,001)
Finance income and other expenses	3	3,101
Income (loss) before income taxes	188,738	(40,004)
Income tax recovery (expense):		
Current	(25,408)	(15,437)
Deferred	(12,302)	25,075
	(37,710)	9,638
Net income (loss)	\$ 151,028	\$ (30,366)
Attributable to:		
Methanex Corporation shareholders	\$ 131,569	\$ (23,398)
Non-controlling interests	19,459	(6,968)
	\$ 151,028	\$ (30,366)
Income (loss) per common share for the period attributable to Methanex Corporation shareholders		
Basic net income (loss) per common share	\$ 1.47	\$ (0.26)
Diluted net income (loss) per common share (note 6)	\$ 1.46	\$ (0.26)
Weighted average number of common shares outstanding (note 6)	89,786,855	89,718,730
Diluted weighted average number of common shares outstanding (note 6)	89,856,092	89,767,900

See accompanying notes to condensed consolidated interim financial statements.

Methanex Corporation**Consolidated Statements of Comprehensive Income (Loss) (unaudited)***(thousands of U.S. dollars)*

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Net income (loss)	\$ 151,028	\$ (30,366)
Other comprehensive income (loss):		
Items that may be reclassified to income:		
Change in fair value of cash flow hedges (note 9)	(54,502)	(49,719)
Forward element excluded from hedging relationships (note 9)	34,533	31,710
Taxes on above items	6,556	6,015
	(13,413)	(11,994)
Comprehensive income (loss)	\$ 137,615	\$ (42,360)
Attributable to:		
Methanex Corporation shareholders	\$ 118,156	\$ (35,392)
Non-controlling interests	19,459	(6,968)
	\$ 137,615	\$ (42,360)

See accompanying notes to condensed consolidated interim financial statements.

Methanex Corporation
Consolidated Statements of Financial Position (unaudited)
(thousands of U.S. dollars)

AS AT	Mar 31 2017	Dec 31 2016
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 315,133	\$ 223,890
Trade and other receivables	513,576	499,603
Inventories (note 2)	351,363	281,328
Prepaid expenses	23,442	20,846
	1,203,514	1,025,667
Non-current assets:		
Property, plant and equipment (note 3)	3,079,107	3,117,469
Investment in associate (note 4)	189,864	197,402
Deferred income tax assets	128,689	137,341
Other assets	78,581	78,784
	3,476,241	3,530,996
	\$ 4,679,755	\$ 4,556,663
LIABILITIES AND EQUITY		
Current liabilities:		
Trade, other payables and accrued liabilities	\$ 574,887	\$ 523,216
Current maturities on long-term debt (note 5)	55,534	53,997
Current maturities on other long-term liabilities	35,212	29,720
	665,633	606,933
Non-current liabilities:		
Long-term debt (note 5)	1,476,944	1,502,209
Other long-term liabilities	368,871	351,191
Deferred income tax liabilities	288,430	290,980
	2,134,245	2,144,380
Equity:		
Capital stock	509,362	511,465
Contributed surplus	2,212	2,568
Retained earnings	1,201,367	1,124,104
Accumulated other comprehensive loss	(54,715)	(41,302)
Shareholders' equity	1,658,226	1,596,835
Non-controlling interests	221,651	208,515
Total equity	1,879,877	1,805,350
	\$ 4,679,755	\$ 4,556,663

See accompanying notes to condensed consolidated interim financial statements.

Methanex Corporation

Consolidated Statements of Changes in Equity (unaudited)

(thousands of U.S. dollars, except number of common shares)

	Number of Common Shares	Capital Stock	Contributed Surplus	Retained Earnings	Accumulated Other Comprehensive Loss	Shareholders' Equity	Non- Controlling Interests	Total Equity
Balance, December 31, 2015	89,671,198	\$509,464	\$2,426	\$1,235,615	\$(27,776)	\$1,719,729	\$248,844	\$1,968,573
Net loss	—	—	—	(23,398)	—	(23,398)	(6,968)	(30,366)
Other comprehensive loss	—	—	—	—	(11,994)	(11,994)	—	(11,994)
Compensation expense recorded for stock options	—	—	194	—	—	194	—	194
Issue of shares on exercise of stock options	125,040	798	—	—	—	798	—	798
Reclassification of grant date fair value on exercise of stock options	—	257	(257)	—	—	—	—	—
Dividend payments to Methanex Corporation shareholders	—	—	—	(24,705)	—	(24,705)	—	(24,705)
Distributions made and accrued to non-controlling interests	—	—	—	—	—	—	(5,965)	(5,965)
Balance, March 31, 2016	89,796,238	\$510,519	\$2,363	\$1,187,512	\$(39,770)	\$1,660,624	\$235,911	\$1,896,535
Net income (loss)	—	—	—	10,853	—	10,853	(8,712)	2,141
Other comprehensive loss	—	—	—	(169)	(1,532)	(1,701)	—	(1,701)
Compensation expense recorded for stock options	—	—	443	—	—	443	—	443
Issue of shares on exercise of stock options	28,100	708	—	—	—	708	—	708
Reclassification of grant date fair value on exercise of stock options	—	238	(238)	—	—	—	—	—
Dividend payments to Methanex Corporation shareholders	—	—	—	(74,092)	—	(74,092)	—	(74,092)
Distributions made and accrued to non-controlling interests	—	—	—	—	—	—	(18,709)	(18,709)
Equity contributions by non-controlling interests	—	—	—	—	—	—	25	25
Balance, December 31, 2016	89,824,338	\$511,465	\$2,568	\$1,124,104	\$(41,302)	\$1,596,835	\$208,515	\$1,805,350
Net income	—	—	—	131,569	—	131,569	19,459	151,028
Other comprehensive loss	—	—	—	—	(13,413)	(13,413)	—	(13,413)
Compensation expense recorded for stock options	—	—	139	—	—	139	—	139
Issue of shares on exercise of stock options	53,620	1,559	—	—	—	1,559	—	1,559
Reclassification of grant date fair value on exercise of stock options	—	495	(495)	—	—	—	—	—
Payment for shares repurchased	(730,000)	(4,157)	—	(29,585)	—	(33,742)	—	(33,742)
Dividend payments to Methanex Corporation shareholders	—	—	—	(24,721)	—	(24,721)	—	(24,721)
Distributions made and accrued to non-controlling interests	—	—	—	—	—	—	(6,323)	(6,323)
Balance, March 31, 2017	89,147,958	\$509,362	\$2,212	\$1,201,367	\$(54,715)	\$1,658,226	\$221,651	\$1,879,877

See accompanying notes to condensed consolidated interim financial statements.

Methanex Corporation
Consolidated Statements of Cash Flows *(unaudited)*
(thousands of U.S. dollars)

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES		
Net income (loss)	\$ 151,028	\$ (30,366)
Add (deduct) loss (earnings) of associate	(16,989)	227
Dividends received from associate	24,609	28,395
Add (deduct) non-cash items:		
Depreciation and amortization	55,972	52,979
Income tax expense (recovery)	37,710	(9,638)
Share-based compensation expense	12,510	2,883
Finance costs	23,317	21,001
Other	1,405	387
Income taxes paid	(4,663)	(570)
Other cash payments, including share-based compensation	(5,954)	(5,910)
Cash flows from operating activities before undernoted	278,945	59,388
Changes in non-cash working capital (note 8)	(58,291)	10,590
	220,654	69,978
CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES		
Payments for repurchase of shares	(33,742)	—
Dividend payments to Methanex Corporation shareholders	(24,721)	(24,705)
Interest paid	(15,506)	(13,374)
Net proceeds on issue of long-term debt	—	4,593
Repayment of long-term debt	(24,514)	(22,066)
Finance leases	(1,844)	(946)
Distributions to non-controlling interests	—	(500)
Proceeds on issue of shares on exercise of stock options	1,559	798
Changes in non-cash working capital related to financing activities (note 8)	(3,967)	(5,465)
	(102,735)	(61,665)
CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES		
Property, plant and equipment	(19,577)	(15,450)
Other assets	—	(66)
Changes in non-cash working capital related to investing activities (note 8)	(7,099)	27,280
	(26,676)	11,764
Increase in cash and cash equivalents	91,243	20,077
Cash and cash equivalents, beginning of period	223,890	254,934
Cash and cash equivalents, end of period	\$ 315,133	\$ 275,011

See accompanying notes to condensed consolidated interim financial statements.

Methanex Corporation

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

Except where otherwise noted, tabular dollar amounts are stated in thousands of U.S. dollars.

1. Basis of presentation:

Methanex Corporation ("the Company") is an incorporated entity with corporate offices in Vancouver, Canada. The Company's operations consist of the production and sale of methanol, a commodity chemical. The Company is the world's largest producer and supplier of methanol to the major international markets of Asia Pacific, North America, Europe and South America.

These condensed consolidated interim financial statements are prepared in accordance with *International Accounting Standards ("IAS") 34, Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB") on a basis consistent with those followed in the most recent annual consolidated financial statements.

These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and were approved and authorized for issue by the Audit, Finance & Risk Committee of the Board of Directors on April 26, 2017.

These condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2016.

2. Inventories:

Inventories are valued at the lower of cost, determined on a first-in first-out basis, and estimated net realizable value. The amount of inventories recognized as an expense in cost of sales and operating expenses and depreciation and amortization for the three months ended March 31, 2017 is \$544 million (March 31, 2016 - \$386 million).

3. Property, plant and equipment:

	Buildings, Plant Installations & Machinery	Finance Leases	Other	Total
Cost at March 31, 2017	\$ 4,569,108	\$ 208,508	\$ 270,872	\$ 5,048,488
Accumulated depreciation at March 31, 2017	1,804,479	22,464	142,438	1,969,381
Net book value at March 31, 2017	\$ 2,764,629	\$ 186,044	\$ 128,434	\$ 3,079,107
Cost at December 31, 2016	\$ 4,549,816	\$ 206,260	\$ 272,878	\$ 5,028,954
Accumulated depreciation at December 31, 2016	1,752,540	18,557	140,388	1,911,485
Net book value at December 31, 2016	\$ 2,797,276	\$ 187,703	\$ 132,490	\$ 3,117,469

4. Interest in Atlas joint venture:

- a) The Company has a 63.1% equity interest in Atlas Methanol Company Unlimited ("Atlas"). Atlas owns a 1.8 million tonne per year methanol production facility in Trinidad. The Company accounts for its interest in Atlas using the equity method. Summarized financial information of Atlas (100% basis) is as follows:

Statements of financial position	Mar 31 2017	Dec 31 2016
Cash and cash equivalents	\$ 10,888	\$ 15,530
Other current assets	63,274	45,219
Non-current assets	315,679	324,297
Current liabilities	(43,430)	(24,783)
Other long-term liabilities, including current maturities	(166,478)	(168,253)
Net assets at 100%	179,933	192,010
Net assets at 63.1%	113,538	121,158
Long-term receivable from Atlas	76,326	76,244
Investment in associate	\$ 189,864	\$ 197,402

Statements of income	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Revenue	\$ 115,209	\$ 22,373
Cost of sales and depreciation and amortization	(70,417)	(18,176)
Operating income	44,792	4,197
Finance costs, finance income and other expenses	(2,878)	(3,092)
Income tax expense	(14,990)	(1,465)
Net earnings (loss) at 100%	26,924	(360)
Earnings (loss) of associate at 63.1%	\$ 16,989	\$ (227)
Dividends received from associate	\$ 24,609	\$ 28,395

b) Contingent liability:

The Board of Inland Revenue of Trinidad and Tobago has issued assessments against Atlas in respect of the 2005 to 2010 financial years. All subsequent tax years remain open to assessment. The assessments relate to the pricing arrangements of certain long-term fixed price sales contracts from 2005 to 2019 related to methanol produced by Atlas. Atlas had partial relief from corporation income tax until late July 2014.

The Company has lodged objections to the assessments. Based on the merits of the cases and legal interpretation, management believes its position should be sustained.

5. Long-term debt:

As at	Mar 31 2017	Dec 31 2016
Unsecured notes		
\$350 million at 3.25% due December 15, 2019	\$ 347,356	\$ 347,126
\$250 million at 5.25% due March 1, 2022	247,780	247,685
\$300 million at 4.25% due December 1, 2024	296,613	296,529
\$300 million at 5.65% due December 1, 2044	295,102	295,084
	1,186,851	1,186,424
Egypt limited recourse debt facilities	266,448	288,515
Other limited recourse debt facilities	79,179	81,267
Total long-term debt¹	1,532,478	1,556,206
Less current maturities	(55,534)	(53,997)
	\$ 1,476,944	\$ 1,502,209

¹ Long-term debt is presented net of deferred financing fees.

During the quarter ended March 31, 2017, the Company made repayments on its Egypt limited recourse debt facilities of \$22.4 million, and made repayments of \$2.1 million on its other limited recourse debt facilities. Other limited recourse debt facilities relates to financing for certain of our ocean going vessels which we own through less than wholly-owned entities under the Company's control.

The Company maintains a \$300 million committed revolving credit facility with a syndicate of highly rated financial institutions that expires in December 2019. Significant covenant and default provisions of the facility include:

- a) the obligation to maintain an EBITDA to interest coverage ratio of greater than 2:1 calculated on a four-quarter trailing basis and a debt to capitalization ratio of less than or equal to 55%, both ratios calculated in accordance with definitions in the credit agreement that include adjustments to the limited recourse subsidiaries,
- b) a default if payment is accelerated by a creditor on any indebtedness of \$50 million or more of the Company and its subsidiaries, except for the limited recourse subsidiaries, and
- c) a default if a default occurs that permits a creditor to demand repayment on any other indebtedness of \$50 million or more of the Company and its subsidiaries, except for the limited recourse subsidiaries.

The limited recourse debt facilities are described as limited recourse as they are secured only by the assets of the entity that carries the debt. Accordingly, the lenders to the limited recourse debt facilities have no recourse to the Company or its other subsidiaries.

The Egypt limited recourse debt facilities have covenants and default provisions that apply only to the Egypt entity, including restrictions on the incurrence of additional indebtedness and a requirement to fulfill certain conditions before the payment of cash or other shareholder distributions. Certain conditions have not been met, resulting in a restriction on shareholder distributions from the Egypt entity. As of March 31, 2017, the Egypt cash balance on a 100% ownership basis was \$53 million. The Egypt entity continues to be able to fully utilize its funds for operating, capital and financing needs, including the repayment of the Egypt limited recourse debt facilities.

Failure to comply with any of the covenants or default provisions of the long-term debt facilities described above could result in a default under the applicable credit agreement that would allow the lenders to not fund future loan requests, accelerate the due date of the principal and accrued interest on any outstanding loans or restrict the payment of cash or other distributions.

As at March 31, 2017, management believes the Company was in compliance with all significant terms and default provisions related to long-term debt obligations.

6. Net income (loss) per common share:

Diluted net income (loss) per common share is calculated by considering the potential dilution that would occur if outstanding stock options and, under certain circumstances, tandem share appreciation rights ("TSARs") were exercised or converted to common shares.

Outstanding TSARs may be settled in cash or common shares at the holder's option and for purposes of calculating diluted net income (loss) per common share, the more dilutive of the cash-settled and equity-settled method is used, regardless of how the plan is accounted for. Accordingly, TSARs that are accounted for using the cash-settled method will require adjustments to the numerator and denominator if the equity-settled method is determined to have a dilutive effect on diluted net income (loss) per common share as compared to the cash-settled method. The cash-settled method was more dilutive for the three months ended March 31, 2017, and no adjustment was required for the numerator or the denominator. For the three months ended March 31, 2016, the equity-settled method was more dilutive and an adjustment was required for both the numerator and the denominator.

Stock options and, if calculated using the equity-settled method, TSARs are considered dilutive when the average market price of the Company's common shares during the period disclosed exceeds the exercise price of the stock option or TSAR. For the three months ended March 31, 2017, stock options were considered dilutive resulting in an adjustment to the denominator. For the three months ended March 31, 2016, the Company incurred a net loss attributable to Methanex shareholders and therefore exclusion of the stock options was more dilutive.

A reconciliation of the numerator used for the purpose of calculating diluted net income (loss) per common share is as follows:

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Numerator for basic net income (loss) per common share	\$ 131,569	\$ (23,398)
Adjustment for the effect of TSARs:		
Cash-settled recovery included in net income	—	1,577
Equity-settled expense	—	(1,863)
Numerator for diluted net income (loss) per common share	\$ 131,569	\$ (23,684)

A reconciliation of the denominator used for the purposes of calculating diluted net income (loss) per common share is as follows:

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Denominator for basic net income (loss) per common share	89,786,855	89,718,730
Effect of dilutive stock options	69,237	—
Effect of dilutive TSARs	—	49,170
Denominator for diluted net income (loss) per common share	89,856,092	89,767,900

7. Share-based compensation:

a) Share appreciation rights ("SARs"), TSARs and stock options:

(i) Outstanding units:

Information regarding units outstanding at March 31, 2017 is as follows:

(per share amounts in USD)	SARs		TSARs	
	Number of Units	Weighted Average Exercise Price	Number of Units	Weighted Average Exercise Price
Outstanding at December 31, 2016	1,511,485	\$42.68	2,416,111	\$42.10
Granted	167,600	50.15	340,200	50.17
Exercised	(88,106)	27.13	(118,305)	27.17
Cancelled	(5,000)	25.22	—	—
Outstanding at March 31, 2017	1,585,979	\$44.39	2,638,006	\$43.81

(per share amounts in USD)	Stock Options	
	Number of Units	Weighted Average Exercise Price
Outstanding at December 31, 2016	344,767	\$40.91
Granted	31,400	50.17
Exercised	(53,620)	29.07
Cancelled	(5,200)	55.22
Outstanding at March 31, 2017	317,347	\$43.59

Range of Exercise Prices (per share amounts in USD)	Units Outstanding at March 31, 2017			Units Exercisable at March 31, 2017	
	Weighted Average Remaining Contractual Life (Years)	Number of Units Outstanding	Weighted Average Exercise Price	Number of Units Exercisable	Weighted Average Exercise Price
SARs:					
\$25.22 to \$35.51	3.93	672,260	\$32.72	427,771	\$31.66
\$38.24 to \$73.13	4.48	913,719	52.97	646,644	53.26
	4.25	1,585,979	\$44.39	1,074,415	\$44.66
TSARs:					
\$25.22 to \$35.51	3.82	1,111,325	\$32.75	730,980	\$31.78
\$38.24 to \$73.13	4.52	1,526,681	51.86	1,052,538	51.91
	4.23	2,638,006	\$43.81	1,783,518	\$43.66
Stock options:					
\$25.22 to \$35.51	3.64	143,350	\$32.50	97,346	\$31.51
\$38.24 to \$73.13	4.44	173,997	52.73	125,758	52.98
	4.08	317,347	\$43.59	223,104	\$43.61

(ii) Compensation expense related to SARs and TSARs:

Compensation expense for SARs and TSARs is measured based on their fair value and is recognized over the vesting period. Changes in fair value each period are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value at March 31, 2017 was \$47.6 million compared with the recorded liability of \$41.4 million. The difference between the fair value and the recorded liability of \$6.2 million will be recognized over the weighted average remaining vesting period of approximately 1.8 years. The weighted average fair value was estimated at March 31, 2017 using the Black-Scholes option pricing model.

For the three months ended March 31, 2017, compensation expense related to SARs and TSARs included an expense in cost of sales and operating expenses of \$9.1 million (2016 - \$2.4 million). This included an expense of \$6.4 million (2016 - recovery of \$0.5 million) related to the effect of the change in the Company's share price for the three months ended March 31, 2017.

(iii) Compensation expense related to stock options:

For the three months ended March 31, 2017, compensation expense related to stock options included in cost of sales and operating expenses was \$0.1 million (2016 - \$0.2 million). The fair value of each stock option grant was estimated on the grant date using the Black-Scholes option pricing model.

b) Deferred, restricted and performance share units:

Deferred, restricted and performance share units outstanding at March 31, 2017 are as follows:

	Number of Deferred Share Units	Number of Restricted Share Units	Number of Performances Share Units
Outstanding at December 31, 2016	251,017	18,649	572,272
Granted	6,505	8,100	163,500
Performance factor impact on redemption¹	—	—	(102,557)
Granted in-lieu of dividends	1,424	160	3,551
Redeemed	(13,789)	—	(34,186)
Cancelled	—	—	(3,967)
Outstanding at March 31, 2017	245,157	26,909	598,613

¹ Performance share units have a feature where the ultimate number of units that vest are adjusted by a performance factor of the original grant as determined by the Company's total shareholder return in relation to a predetermined target over the period to vesting. These units relate to performance share units redeemed in the quarter ended March 31, 2017.

Compensation expense for deferred, restricted and performance share units is measured at fair value based on the market value of the Company's common shares and is recognized over the vesting period. Changes in fair value are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value of deferred, restricted and performance share units at March 31, 2017 was \$23.7 million compared with the recorded liability of \$18.8 million. The difference between the fair value and the recorded liability of \$4.9 million will be recognized over the weighted average remaining vesting period of approximately 2.0 years.

For the three months ended March 31, 2017, compensation expense related to deferred, restricted and performance share units included in cost of sales and operating expenses was an expense of \$4.1 million (2016 - \$0.4 million). This included an expense of \$3.2 million (2016 - recovery of \$0.6 million) related to the effect of the change in the Company's share price for the three months ended March 31, 2017.

8. Changes in non-cash working capital:

Changes in non-cash working capital for the three months ended March 31, 2017 were as follows:

	Three Months Ended	
	Mar 31 2017	Mar 31 2016
Changes in non-cash working capital:		
Trade and other receivables	\$ (13,973)	\$ 119,756
Inventories	(70,035)	6,809
Prepaid expenses	(2,596)	5,551
Trade, other payables and accrued liabilities	51,671	(77,075)
	(34,933)	55,041
Adjustments for items not having a cash effect and working capital changes relating to taxes and interest paid	(34,424)	(22,636)
Changes in non-cash working capital having a cash effect	\$ (69,357)	\$ 32,405
These changes relate to the following activities:		
Operating	\$ (58,291)	\$ 10,590
Financing	(3,967)	(5,465)
Investing	(7,099)	27,280
Changes in non-cash working capital	\$ (69,357)	\$ 32,405

9. Financial instruments:

Financial instruments are either measured at amortized cost or fair value.

In the normal course of business, the Company's assets, liabilities and forecasted transactions, as reported in U.S. dollars, are impacted by various market risks including, but not limited to, natural gas prices and currency exchange rates. The time frame and manner in which the Company manages those risks varies for each item based on the Company's assessment of the risk and the available alternatives for mitigating risks.

The Company uses derivatives as part of its risk management program to mitigate variability associated with changing market values. Changes in fair value of derivative financial instruments are recorded in earnings unless the instruments are designated as cash flow hedges. The Company designates as cash flow hedges derivative financial instruments to hedge its risk exposure to fluctuations in natural gas prices and derivative financial instruments to hedge its risk exposure to fluctuations in the euro compared to the U.S. dollar.

The fair value of derivative instruments is determined based on industry-accepted valuation models using market observable inputs and are classified within Level 2 of the fair value hierarchy. The fair value of all of the Company's derivative contracts as presented in the consolidated statements of financial position are determined based on present values and the discount rates used are adjusted for credit risk. The effective portion of the changes in fair value of derivative financial instruments designated as cash flow hedges is recorded in other comprehensive income. The spot element of forward contracts in the hedging relationships is recorded in other comprehensive income as the change in fair value of cash flow hedges. The change in the fair value of the forward element of forward contracts is recorded separately in other comprehensive income as the forward element excluded from hedging relationship.

Until settled, the fair value of the derivative financial instruments will fluctuate based on changes in commodity prices or foreign currency exchange rates.

Natural gas forward contracts

The Company manages its exposure to changes in natural gas prices for a portion of their North American natural gas requirements by executing a number of fixed price forward contracts.

The Company has entered into forward contracts to manage its exposure to changes in natural gas prices for the Geismar 2 facility which it has designated as cash flow hedges. The Company has also entered into physical forward contracts to manage its exposure to changes in natural gas prices for the Medicine Hat facility over the period 2017 to 2022. During the first quarter of 2017, the Company has designated contracts for the 2021 and 2022 period as cash flow hedges for its highly probable forecast natural gas purchases in Medicine Hat. Other costs incurred to transport natural gas from the contracted delivery point, either Henry Hub or AECO, to the relevant production facility represent an insignificant portion of the overall underlying risk and are recognized as incurred outside of the hedging relationship.

As at March 31, 2017, the Company had outstanding forward contracts designated as cash flow hedges with a notional amount of \$494 million (December 31, 2016 - \$484 million) and a net negative fair value of \$81.2 million (December 31, 2016 - \$61.9 million) included in other long-term liabilities.

Euro forward exchange contracts

The Company manages its foreign currency exposure to euro denominated sales by executing a number of forward contracts which it has designated as cash flow hedges for its highly probable forecast euro collections.

As at March 31, 2017, the Company had outstanding forward exchange contracts designated as cash flow hedges to sell a notional amount of 126 million euros (December 31, 2016 - 92 million euros). The euro contracts had a negative fair value of \$0.4 million included in current liabilities (December 31, 2016 - positive fair value \$0.3 million included in current assets).

Fair value

The fair value of the Company's derivative financial instruments as disclosed above are determined based on Bloomberg quoted market prices and confirmations received from counterparties, which are adjusted for credit risk.

The table below shows net cash flows for derivative hedging instruments, excluding credit risk adjustments, based upon contracted settlement dates. The amounts reflect the maturity profile of the hedging instruments and are subject to change based on the prevailing market rate at each of the future settlement dates. Financial asset derivative positions are held with investment-grade counterparties and therefore the settlement day risk exposure is considered to be negligible.

	Cash inflows (outflows) by term to maturity				Total
	1 year or less	1-3 years	3-5 years	More than 5 years	
Natural gas forward contracts	2,399	(13,077)	(22,618)	(64,774)	\$ (98,070)
Euro forward exchange contracts	(379)	—	—	—	\$ (379)

The carrying values of the Company's financial instruments approximate their fair values, except as follows:

As at	March 31, 2017	
	Carrying Value	Fair Value
Long-term debt excluding deferred financing fees	\$ 1,544,485	\$ 1,561,164

Long-term debt consists of limited recourse debt facilities and unsecured notes. There is no publicly traded market for the limited recourse debt facilities. The fair value of the limited recourse debt facilities as disclosed on a recurring basis and categorized as Level 2 within the fair value hierarchy is estimated by reference to current market rates as at the reporting date. The fair value of the unsecured notes disclosed on a recurring basis and also categorized as Level 2 within the fair value hierarchy is estimated using quoted prices and yields as at the reporting date. The fair value of the Company's long term debt will fluctuate until maturity.

Methanex Corporation
Quarterly History (unaudited)

	Q1 2017	2016	Q4	Q3	Q2	Q1	2015	Q4	Q3	Q2	Q1
METHANOL SALES VOLUME (thousands of tonnes)											
Methanex-produced ¹	1,756	6,828	1,750	1,860	1,689	1,529	5,050	1,372	1,238	1,203	1,237
Purchased methanol	512	1,892	526	411	533	422	2,780	636	679	813	652
Commission sales ¹	304	758	245	205	140	168	641	178	169	109	185
	2,572	9,478	2,521	2,476	2,362	2,119	8,471	2,186	2,086	2,125	2,074
METHANOL PRODUCTION (thousands of tonnes)											
New Zealand	533	2,181	536	559	577	509	1,856	412	476	487	481
Geismar (Louisiana, USA)	493	2,055	526	519	527	483	959	244	259	276	180
Trinidad (Methanex interest)	396	1,605	455	420	417	313	1,644	432	398	419	395
Egypt (50% interest)	159	293	96	69	53	75	74	58	—	8	8
Medicine Hat (Canada)	118	488	92	114	123	159	456	155	123	51	127
Chile	167	395	154	68	73	100	204	88	3	40	73
	1,866	7,017	1,859	1,749	1,770	1,639	5,193	1,389	1,259	1,281	1,264
AVERAGE REALIZED METHANOL PRICE ²											
(\$/tonne)	365	242	278	236	223	230	322	277	323	350	337
(\$/gallon)	1.10	0.73	0.84	0.71	0.67	0.69	0.97	0.83	0.97	1.05	1.01
PER SHARE INFORMATION (\$ per common share attributable to Methanex shareholders)											
Adjusted net income (loss)	1.56	(0.17)	0.46	(0.01)	(0.34)	(0.27)	1.20	0.16	0.26	0.56	0.23
Basic net income (loss)	1.47	(0.14)	0.28	(0.12)	(0.03)	(0.26)	2.21	0.10	0.87	1.15	0.09
Diluted net income (loss)	1.46	(0.14)	0.28	(0.12)	(0.08)	(0.26)	2.01	0.10	0.54	1.15	0.09

¹ Methanex-produced methanol represents our equity share of volume produced at our facilities and excludes volume marketed on a commission basis related to the 36.9% of the Atlas facility and 50% of the Egypt facility that we do not own. Methanex-produced methanol includes any volume produced by Chile using natural gas supplied from Argentina under a tolling arrangement ("Tolling Volume"). There has been no Tolling Volume produced since the fourth quarter of 2015.

² Averagerealized price is calculated as revenue, excluding commissions earned and the Egypt non-controlling interest share of revenue, but including an amount representing our share of Atlas revenue, divided by the total sales volume of Methanex-produced and purchased methanol, but excluding Tolling Volume.